Wednesday, September 23, 2026
TagsIII

Tag: III

Healthcare

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem...

BFN's Desk - 0
Healthcare

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

BFN's Desk - 0
Healthcare

Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a targeted therapy in NSCLC with MET Alterations

BFN's Desk - 0
Healthcare

Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally...

BFN's Desk - 0
Automobile

Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

BFN's Desk - 0
Automobile

Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

BFN's Desk - 0
Politics

Auction for Sale (issue/re-issue) of (i) 7.32% GS 2030’, (ii) ‘7.18% GS 2037’, (iii) ‘7.25% GS 2063’, and (iv) ‘New GOI SGrB 2033’

BFN's Desk - 0
Featured

Merck Strengthens Oncology Portfolio Through Commercialization Agreement With Abbisko for Phase III Asset Pimicotinib

BFN's Desk - 0
Insurance-Tips

Crestview Partners III GP L.P. Takes $156.89 Million Position in Fidelis Insurance Holdings Limited (NYSE:FIHL)

BFN's Desk - 0
Politics

Auction for Sale (re-issue) of (i) ‘7.37% GS 2028’, (ii) ‘7.18% GS 2033’ and (iii) ‘7.30% GS 2053’

BFN's Desk - 0
123Page 1 of 3

Most Read

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

ABOUT US

Newspaper is your news, entertainment, music fashion website. We provide you with the latest breaking news and videos straight from the entertainment industry.

Contact us: [email protected]

FOLLOW US

© Newspaper WordPress Theme by TagDiv